DoD Breast Cancer, Transformative Breast Cancer Consortium Award | W81XWH 22 BCRP TBCCA

Opportunity Information: Apply for W81XWH 22 BCRP TBCCA

The DoD Breast Cancer Transformative Breast Cancer Consortium Award (Funding Opportunity Number: W81XWH-22-BCRP-TBCCA) is a competitive Department of Defense funding mechanism meant to back large, tightly coordinated research consortia that can genuinely change outcomes for people living with breast cancer or those at elevated risk. The central idea is not incremental progress or another well-run collaborative network, but a focused push for work that can disrupt the current breast cancer landscape and accelerate the field toward the mission of ending breast cancer. A key emphasis is that the "transformation" should be visible in peoples lives (for example, meaningfully reducing risk, preventing disease, improving survival, or reducing suffering), rather than primarily improving the research or healthcare system itself.

Structurally, the award requires a true consortium model: a minimum of four and a maximum of five project teams, each pursuing a distinct project that fits under a single, unifying central hypothesis. The teams cannot be clustered at one place; no more than two project teams may be based at the same institution, which is meant to drive multi-institutional collaboration rather than a single-center program with satellite partners. Each team has its own Principal Investigator, but the overall effort must be led by a Consortium Director, and the teams are expected to function as an integrated machine rather than as semi-independent projects. The application must show that every component is working toward the shared hypothesis and that the scientific dependencies between projects are real and necessary.

A major requirement is deep, substantive integration across the consortium. Reviewers are looking for more than a communication plan, a management chart, or a promise to hold regular meetings. Applicants must explain exactly how the research will be integrated in practice: how data, samples, analytic approaches, model systems, experimental pipelines, or decision points will flow across teams, and how the consortium design enables questions to be answered that no single team could resolve alone. Integration is expected not only at the administrative and logistical level, but within the core scientific processes, with clear mechanisms that create synergy and enforce shared progress toward the central hypothesis.

The science itself must be paradigm-shifting and genuinely new. The opportunity calls for ideas that tackle fundamental, overarching problems in breast cancer, ideally aligned with one or more of the FY22 Breast Cancer Research Program (BCRP) Overarching Challenges. Applicants can propose a different fundamental issue if they justify why it fits the intent of the mechanism, but that different issue must still be coupled with at least one FY22 BCRP Overarching Challenge. The expectation is an "ecologic" approach, meaning the consortium should pull together multiple disciplines and perspectives to address breast cancer as a complex problem with interacting biological, clinical, environmental, behavioral, and other contributing factors, rather than treating it as a narrow, single-variable scientific question. The plan should also make room for addressing important aspects of the hypothesis that have not been adequately studied or answered before.

Another distinctive feature is built-in flexibility for innovation during the project period. The award includes funds reserved for "seed projects," which are meant to support brand new, high-risk/high-reward ideas that emerge from the consortiums ongoing findings. In other words, the program is designed to allow the consortium to pivot into promising directions discovered midstream, without being locked entirely into what was known at the time of application.

The program also sets clear boundaries around what it is not trying to fund. It explicitly states that this award is not intended to replace, supplement, duplicate, or compete with other major collaborative efforts such as NCI SPOREs, and it should not look like a collection of related program project subprojects packaged together. Likewise, if a proposed effort fits the scope and criteria of the FY22 BCRP Breakthrough Awards (Levels 1 through 4), it should be submitted under those mechanisms instead, not under this consortium award. While phase 1 clinical trials and partnerships with pharmaceutical or biotech companies are allowed where appropriate, a clinical trial is not required and should not be the primary thrust of the consortium.

To keep the focus on transformative, systems-level breakthroughs rather than narrower or more routine research programs, the solicitation notes several examples of approaches that would not meet the intent if they are the primary effort or central hypothesis. These include proposals that resemble NCI Program Project or SPORE applications, broad drug screens or testing therapeutic "cocktails," work centered on a single gene or protein, creating a new derivative or formulation of an existing drug, genomic landscape mapping as the main activity, or incremental improvements to existing screening technologies such as mammography or MRI.

Administratively, this opportunity was issued by the Department of Defense, Department of the Army, through USAMRAA, with a posting date of March 16, 2022, and an original closing date of July 27, 2022. It is listed as a discretionary opportunity in the science and technology/research and development category (CFDA 12.420) and uses grant and cooperative agreement instruments. Eligibility is described as unrestricted (open to any entity type), subject to any additional eligibility clarifications in the full announcement. The listing indicates an expected single award, and the public-facing "award ceiling" field is shown as 0, which typically signals that the specific ceiling is defined in the full funding announcement rather than in the summary record.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Breast Cancer, Transformative Breast Cancer Consortium Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Mar 16, 2022.
• Applicants must submit their applications by Jul 27, 2022. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 1 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 22 BCRP TBCCA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: